Cytek Biosciences, Inc.

CTKBNASDAQHealthcare● Active

$4.02

$-0.07(-1.63%)

Market Cap$519566456

P/E Ratio—

52W High$6.18

52W Low$2.9

Avg Volume794K

Open$4.12

Beta1.19

Net Income Financials Revenue

Cytek Biosciences, Inc. (CTKB) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

CTKB · net income · updated Jun 8, 2026

Core profitability metrics

CTKB · net income · margin · TTM · CAGR

Net income was −$66.5M for FY2025 (fiscal year ending 2025-12-31), down 1005.3% year-over-year. Net profit margin was -33.0%. Based on available data, Cytek Biosciences, Inc. has been profitable since at least 2020.

FY2025 Net Income−$66.5M▼ -1005.3% YoY

Trailing 12M (TTM)−$74.0Mtrailing 4 quarters sum

Net Profit Margin-33.0%−$66.5M ÷ $201.5M

YoY Change-1005.3%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2020

▸ FMP /income-statement · Annual · CTKB net income history · CTKB profit margin

Annual net income data

CTKB · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$66.5M▼ 1005.3%-33.0%$201.5M

FY2024Loss−$6.0M▲ +50.4%-3.0%$200.5M

FY2023Loss−$12.1M▼ 571.6%-6.3%$193.0M

FY2022$2.6M▼ 14.2%1.6%$164.0M

FY2021$3.0M▼ 84.5%2.4%$128.0M

Net income vs peers (Healthcare)

CTKB vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Cytek Biosciences, Inc.YOU

CTKB

−$66.5M-1005.3%-33.0%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Cytek Biosciences, Inc. (CTKB) reported net income of −$66.5M for FY2025 (fiscal year ending 2025-12-31), down 1005.3% year-over-year. The net profit margin was -33.0% — meaning the company kept $-0.33 of every dollar of revenue as profit.

Based on available data, Cytek Biosciences, Inc. has been profitable since at least 2020. Net income reached a peak of $19.4M in FY2020. Data available for 7 fiscal years.

Cytek Biosciences, Inc.'s net profit margin was -33.0% for FY2025, based on the latest annual results.

Investors sometimes search for "Cytek Biosciences, Inc. net worth" — the company's market capitalization is a separate figure from CTKB net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

CTKB net income · 4 questions

Cytek Biosciences, Inc. is not currently profitable on an annual basis. The company reported a net loss of $66.5M for FY2025.

is CTKB profitabledoes CTKB make a profitCTKB profitabilityCTKB profitable company

▸ Source: FMP /income-statement · GAAP · Cytek Biosciences, Inc. · Cytek Biosciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026